Clinical trial
Risk of Venous Thromboembolism in Patients Receiving First-Line Chemotherapy for Disseminated Germ Cell Tumours - a Multi-Site Retrospective Cohort Study as Part of the Global Germ-Cell Cancer Group (G3) Consortium
NCT04122430 is registered in ClinicalTrials.gov with Walter and Eliza Hall Institute of Medical Research as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Risk of Venous Thromboembolism in Patients Receiving First-Line Chemotherapy for Disseminated Germ Cell Tumours - a Multi-Site Retrospective Cohort Study as Part of the Global Germ-Cell Cancer Group (G3) Consortium
- Lead sponsor
- Walter and Eliza Hall Institute of Medical Research
- Phase
- Observational
- Overall status
- Completed
- Start date
- December 31, 2015
- Completion date
- October 16, 2020
- Enrollment
- 1,135 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.